Sandoz stock: US Enzeevu launch adds private-label channel
Published on 11/16/2026 at 17:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSWhat Enzeevu adds in the US
- Sandoz launched its aflibercept biosimilar in the United States as an additional treatment option for retinal diseases.
- The private-label agreement creates a second US commercial channel and supports the company's biosimilar expansion strategy.
- Sandoz aims to build a portfolio of more than 100 biosimilars by 2040.
Sandoz announced on Monday, November 16, 2026, the US launch of Enzeevu, an aflibercept biosimilar for retinal diseases, alongside a multi-year private-label agreement. The announcement was carried by finanzen.net.
US launch broadens commercial reach
Enzeevu contains aflibercept-abzv at a 2 mg dose and is approved in a pre-filled syringe. The medicine is indicated for neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic retinopathy and diabetic macular edema. Sandoz said these conditions collectively affect more than 30 million Americans.
The company said Enzeevu is approved in the same dosage form, administration route and presentation as Eylea. It said the product has met US biosimilarity requirements and is interchangeable with the reference medicine for all approved indications.
Private label starts in 2027
Under the new agreement, Sandoz will manufacture Enzeevu for private-label commercialization beginning in mid-2027. The arrangement includes committed volumes from the second half of 2027, but the announcement gives no financial terms or volume figures.
The launch strengthens Sandoz's ophthalmology offering after its US Cimerli acquisition in 2024 and the European Afqlir launch in 2025. It also supports the company's Bio100 ambition to have more than 100 biosimilars in its portfolio by 2040.
Sandoz stock traded at 92.02 euros on Lang & Schwarz at 17:32:49 CET on Monday, November 16, 2026.
Sandoz Group AG
- ISIN: CH1243598427
- Ticker: SDZ
- Home exchange: SIX Swiss Exchange
- Lang & Schwarz price: 92.02 euros on November 16, 2026, at 17:32:49 CET
US healthcare and pharmaceutical shares can be followed in current market reports.
